Base de dados : MEDLINE
Pesquisa : C20.543.480.099 [Categoria DeCS]
Referências encontradas : 16001 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1601 ir para página                         

  1 / 16001 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834048
[Au] Autor:Hill DA; Leahy AB; Sciasci J; O'Neill SP; Reilly A; Balamuth N; Seeholzer SH; Spergel JM; Brown-Whitehorn TF
[Ad] Endereço:Department of Pediatrics, Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
[Ti] Título:Medication contaminants as a potential cause of anaphylaxis to vincristine.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vincristine (VCR) is a vinca alkaloid and common chemotherapeutic that is used to treat multiple pediatric and adult malignancies. Despite its common use, cases of anaphylaxis to VCR are rare and typically isolated to a single individual. We report a series of eight patients with adverse reactions to VCR over the course of 11 months at a single institution, four of which progressed to anaphylaxis and one of which resulted in cardiac arrest. Mass spectrometry analysis of medication lots was performed to test for possible contaminant(s). Our findings highlight the risk of anaphylaxis during therapy with VCR.
[Mh] Termos MeSH primário: Anafilaxia
Contaminação de Medicamentos
Neoplasias/tratamento farmacológico
Vincristina/administração & dosagem
Vincristina/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Anafilaxia/induzido quimicamente
Anafilaxia/mortalidade
Criança
Pré-Escolar
Feminino
Seres Humanos
Lactente
Masculino
Espectrometria de Massas
Fatores de Risco
Vincristina/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
5J49Q6B70F (Vincristine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26761


  2 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779084
[Au] Autor:Bonadonna P; Bonifacio M; Zanotti R
[Ad] Endereço:Allergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
[Ti] Título:Mast Cell Disorders In Drug Hypersensitivity.
[So] Source:Curr Pharm Des;22(45):6862-6869, 2016.
[Is] ISSN:1873-4286
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Mastocytosis is a clonal disease characterized by proliferation and accumulation of mast cells (MC) in different tissues, preferentially skin and bone marrow, leading to a wide variety of clinical manifestations, mainly caused by the inappropriate release of MC mediators. As a consequence, patients with mastocytosis may experience symptoms due to massive MC activation and release of mediators. Anaphylaxis is the most frequent manifestation of this phenomenon. Drugs are possible triggers of anaphylaxis in patients with mastocytosis, even though the association between mastocytosis and drug anaphylaxis does not appear to be as strong as anaphylaxis after hymenoptera sting; nevertheless, MC disorders might be ruled out in cases of severe systemic reactions to drugs. Moreover, the risk of perioperative anaphylaxis in adults appears high, mainly in patients with indolent systemic mastocytosis regardless of skin involvement. Such risk is probably lower in patients who have never experienced anaphylaxis and/or have tolerated previous general anaesthesia. However, data published about drug anaphylaxis in patients with MC disorders are scanty and currently it is not possible to provide clear recommendations.
[Mh] Termos MeSH primário: Anafilaxia/imunologia
Hipersensibilidade a Drogas/imunologia
Mastócitos/imunologia
Mastócitos/patologia
Mastocitose/patologia
[Mh] Termos MeSH secundário: Anafilaxia/diagnóstico
Anafilaxia/epidemiologia
Hipersensibilidade a Drogas/diagnóstico
Hipersensibilidade a Drogas/epidemiologia
Seres Humanos
Mastócitos/efeitos dos fármacos
Mastocitose/diagnóstico
Mastocitose/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.2174/1381612822666160928121857


  3 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28744120
[Au] Autor:Chakraborty S; Kar N; Kumari L; De A; Bera T
[Ad] Endereço:Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India.
[Ti] Título:Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice.
[So] Source:Int J Nanomedicine;12:4849-4868, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Type I hypersensitivity is an allergic reaction characterized by the overactivity of the immune system provoked by normally harmless substances. Glucocorticoids, anti-histamines, or mast cell stabilizers are the choices of treatment for type I hypersensitivity. Even though these drugs have the anti-allergic effect, they can have several side effects in prolong use. Cedrol is the main bioactive compound of with anti-tumor, anti-oxidative, and platelet-activating factor inhibiting properties. METHODS: In this study, the preparation and anti-anaphylactic effect of cedrol-loaded nanostructured lipid carriers (NLCs) were evaluated. NLCs were prepared using Compritol 888 ATO and triolein as lipid phase and vitamin E d-α-tocopherylpolyethyleneglycol 1000 succinate, soya lecithin, and sodium deoxycholate as nanoparticle stabilizers. RESULTS: The average diameter of cedrol-NLCs (CR-NLCs) was 71.2 nm (NLC-C ) and 91.93 nm (NLC-C ). The particle had negative zeta potential values of -31.9 mV (NLC-C ) and -44.5 mV (NLC-C ). Type I anaphylactoid reaction in the animal model is significantly reduced by cedrol and cedrol-NLC. This in vivo activity of cedrol resulted that cedrol suppressed compound 48/80-induced peritoneal mast cell degranulation and histamine release from mast cells. Furthermore, compound 48/80-evoked Ca uptake into mast cells was reduced in a dose-dependent manner by cedrol and cedrol-NLC. Studies confirmed that the inhibition of type I anaphylactoid response in vivo in mice and compound 48/80-induced mast cell activation in vitro are greatly enhanced by the loading of cedrol into the NLCs. The safety of cedrol and CR-NLC was evaluated as selectivity index (SI) with prednisolone and cromolyn sodium as positive control. SI of CR-NLC-C was found to be 11.5-fold greater than both prednisolone and cromolyn sodium. CONCLUSION: Administration of CR-NLC 24 hours before the onset of anaphylaxis can prevent an anaphylactoid reaction. NLCs could be a promising vehicle for the oral delivery of cedrol to protect anaphylactic reactions.
[Mh] Termos MeSH primário: Anafilaxia/tratamento farmacológico
Portadores de Fármacos/química
Mastócitos/efeitos dos fármacos
Nanoestruturas/administração & dosagem
Terpenos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Animais
Degranulação Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Portadores de Fármacos/administração & dosagem
Ácidos Graxos
Feminino
Liberação de Histamina/efeitos dos fármacos
Lipídeos/administração & dosagem
Lipídeos/química
Masculino
Mastócitos/fisiologia
Camundongos Endogâmicos BALB C
Nanopartículas/química
Nanoestruturas/química
Terpenos/farmacologia
Trioleína/química
Vitamina E/química
p-Metoxi-N-metilfenetilamina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Fatty Acids); 0 (Lipids); 0 (Terpenes); 122-32-7 (Triolein); 1406-18-4 (Vitamin E); 18641-57-1 (glyceryl behenate); 4091-50-3 (p-Methoxy-N-methylphenethylamine); 63ZM9703BO (cedrol); O03S90U1F2 (tocophersolan)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S132114


  4 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29269296
[Au] Autor:Hasegawa A; Watanabe M; Osada H; Ogawa M; Ohno H; Yanuma N; Sasaki K; Shimoda M; Shirai J; Ohmori K
[Ad] Endereço:Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan.
[Ti] Título:Influence of glucocorticoids on time-of-day-dependent variations in IgE-, histamine-, and platelet-activating factor-mediated systemic anaphylaxis in different mouse strains.
[So] Source:Biochem Biophys Res Commun;495(3):2184-2188, 2018 01 15.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A time-of-day-dependent variation in IgE-mediated passive systemic anaphylaxis was previously reported in ICR mice. In the present study, we investigated time-of-day-dependent variations in IgE-, histamine-, and platelet-activating factor (PAF)-mediated systemic anaphylaxis in C57BL/6, BALB/c, and NC/Nga mice at 9:00 h and 21:00 h, and evaluated the potential influence of glucocorticoids (GCs) on these variations. We found significant time-of-day-dependent variations in IgE-mediated systemic anaphylaxis in C57BL/6 mice, and in histamine- and PAF-mediated systemic anaphylaxis in BALB/c mice. Significant daily variations in IgE-, histamine-, and PAF-mediated systemic anaphylaxis were not observed in NC/Nga mice. Pretreatment with dexamethasone and adrenalectomy abolished the daily variations in IgE-mediated systemic anaphylaxis in C57BL/6 mice and in PAF-mediated systemic anaphylaxis in BALB/c mice, suggesting that GCs from adrenal glands are pivotal in regulating these variations. In contrast, pretreatment with dexamethasone and adrenalectomy did not abolish the daily variation in histamine-mediated systemic anaphylaxis in BALB/c mice, suggesting that GC-independent and adrenal gland-independent mechanisms are important for the variation. The present study demonstrated that time-of-day-dependent variations in systemic anaphylaxis differed among inbred mouse strains and with anaphylaxis-inducing substances. Thus, mouse strains, time of experiment, and anaphylaxis-inducing substances used must be considered to obtain appropriate experimental results.
[Mh] Termos MeSH primário: Anafilaxia/metabolismo
Ritmo Circadiano
Modelos Animais de Doenças
Glucocorticoides/metabolismo
Histamina/metabolismo
Imunoglobulina E/metabolismo
Fator de Ativação de Plaquetas/metabolismo
[Mh] Termos MeSH secundário: Animais
Masculino
Camundongos/classificação
Camundongos/metabolismo
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
Camundongos Endogâmicos ICR
Especificidade da Espécie
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Platelet Activating Factor); 37341-29-0 (Immunoglobulin E); 820484N8I3 (Histamine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE


  5 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29364614
[Au] Autor:Shumakova AA; Shipelin VA; Trushina EN; Mustaphina OK; Gmoshinsky IV; Khanferyan RA; Khotimchenko SA; Tutelyan VA
[Ti] Título:[Toxicological assessment of nanostructured silica. IV. Immunological and allergological indices in animals sensitized with food allergen and final discussioin].
[So] Source:Vopr Pitan;84(5):102-11, 2015.
[Is] ISSN:0042-8833
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:This paper is the final in a series of publications on the assessment of subacute oral toxicity of nanostructured silica (SiO2). Preparation studied was a commercial nanopowder of SiO2, obtained by hydrolysis of tetrachlorosilane in the gaseous phase with the size of primary nanoparticles (NPs) of 5­30 nm. The experiment was conducted in 95 male Wistar rats weighing 150­180 g, divided into 6 groups numbering 25 (group 1), 26 (group 2), 11 (groups 3­6) of animals. The aqueous dispersion of SiO2 after sonication was administered to animals of groups 2, 4 and 6 for 28 days by intragastric gavage at a dose of 100 mg/kg of body weight per day. Animals of groups 1, 3, and 5 were treated with deionized water. On the 1st, 3d, 5th and 21st day of experiment the rats of groups 1, 2, 3 and 4 were sensitized intraperitoneally with hen's egg ovalbumin (OVA) adsorbed to aluminum hydroxide. Intravenous administration of the challenge dose OVA to rats in groups 1 and 2 was carried out on the 29th day. In the same period animals of groups 3­6 were bled for analysis of cellular immunity. There were evaluated the severity of systemic anaphylaxis reaction, the level of specific IgG antibodies to OVA in sensitized animals, state of erythrocytes, platelets and leukocytes of peripheral blood using standard methods. Using flow cytometry there were measured contents of lymphocyte populations of B-lymphocytes (CD45RA+), total T-lymphocytes (CD3+), T-helper cells (CD4+), T-cytotoxic cells (CD8+), NKcells (CD161a+), phagocytic activity of polymorphonuclear leukocytes in respect of latex particles. Serum levels of TNFα and IL-10 cytokines were determined by ELISA. The result showed that NPs SiO2, at dose of 100 mg/kg body weight had no any marked effect on severity of active anaphylactic shock and level of specific antibodies. The changes in cellular immunity under the influence of nanomaterial had similar direction in sensitized and non-sensitized animals and were more pronounced in the latter. Based on the discussion of the results, together with data from previous publications it was concluded that oral maximum level without observable adverse effect (NOAEL) of nanostructured SiO2 is located below 100 mg/kg body weight.
[Mh] Termos MeSH primário: Anafilaxia/sangue
Hipersensibilidade Alimentar/sangue
Nanopartículas/efeitos adversos
Dióxido de Silício/efeitos adversos
[Mh] Termos MeSH secundário: Anafilaxia/patologia
Animais
Linfócitos B/metabolismo
Linfócitos B/patologia
Linfócitos T CD4-Positivos/metabolismo
Linfócitos T CD4-Positivos/patologia
Linfócitos T CD8-Positivos/metabolismo
Linfócitos T CD8-Positivos/patologia
Hipersensibilidade Alimentar/patologia
Imunoglobulina G/sangue
Interleucina-10/sangue
Masculino
Ratos
Ratos Wistar
Dióxido de Silício/farmacologia
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G); 0 (Tumor Necrosis Factor-alpha); 130068-27-8 (Interleukin-10); 7631-86-9 (Silicon Dioxide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE


  6 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448359
[Au] Autor:Aschenbrenner DS
[Ad] Endereço:Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: daschenbrenner@ndm.edu.
[Ti] Título:Rare Allergic Reaction to Topical Chlorhexidine Gluconate.
[So] Source:Am J Nurs;117(5):20, 2017 May.
[Is] ISSN:1538-7488
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anafilaxia/induzido quimicamente
Anti-Infecciosos Locais/efeitos adversos
Clorexidina/análogos & derivados
[Mh] Termos MeSH secundário: Anafilaxia/enfermagem
Clorexidina/efeitos adversos
Seres Humanos
Vigilância de Produtos Comercializados
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Anti-Infective Agents, Local); MOR84MUD8E (chlorhexidine gluconate); R4KO0DY52L (Chlorhexidine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:AIM; IM; N
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1097/01.NAJ.0000516268.32086.24


  7 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29298144
[Au] Autor:Crowley MP; McDonald V; Scully M
[Ad] Endereço:Guy's and St. Thomas' Hospital, London, United Kingdom maeve.crowley@gstt.nhs.uk.
[Ti] Título:Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab.
[So] Source:N Engl J Med;378(1):92-93, 2018 01 04.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anafilaxia/induzido quimicamente
Anticorpos Monoclonais/uso terapêutico
Fatores Imunológicos/efeitos adversos
Púrpura Trombocitopênica Trombótica/tratamento farmacológico
Rituximab/efeitos adversos
[Mh] Termos MeSH secundário: Proteína ADAMTS13/deficiência
Proteína ADAMTS13/imunologia
Feminino
Seres Humanos
Fatores Imunológicos/uso terapêutico
Meia-Idade
Rituximab/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Immunologic Factors); 4F4X42SYQ6 (Rituximab); EC 3.4.24.87 (ADAMTS13 Protein); EC 3.4.24.87 (ADAMTS13 protein, human); M95KG522R0 (ofatumumab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE


  8 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29257365
[Au] Autor:Thompson D
[Ti] Título:RELIABLE ALLERGY RESOURCES.
[So] Source:Aust Nurs Midwifery J;24(7):24, 2017 02.
[Is] ISSN:2202-7114
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Allergic conditions now affect 20% of the Australian population (Mullins et al. 2015). This means that nurses in different clinical practice fields will be involved in involved in caring for patients who may also have an allergic condition.
[Mh] Termos MeSH primário: Anafilaxia/enfermagem
Educação Continuada em Enfermagem
Hipersensibilidade/enfermagem
[Mh] Termos MeSH secundário: Seres Humanos
Especialidades de Enfermagem/educação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  9 / 16001 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245212
[Au] Autor:Kang Y; Park SY; Noh S; Kim J; Seo B; Kwon OY; Kwon HS; Cho YS; Moon HB; Kim TB
[Ad] Endereço:aDepartment of Internal MedicinebDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
[Ti] Título:Case report: A first case of flaxseed-induced anaphylaxis in Korea.
[So] Source:Medicine (Baltimore);96(49):e8220, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Anaphylaxis is a serious, generalized allergic reaction typically triggered by drugs, food, and bee venom, which can be life-threatening. Seeds are one of the major food allergens and can cause anaphylaxis as well as systemic hypersensitivity reactions. Flaxseed has been widely used crop for numerous purposes, such as in alternative medicine and as a dietary supplement, hypersensitivity to it has rarely been reported. PATIENT CONCERNS: A 42-year-old female presenting with facial edema, dyspnea and urticaria after ingested half teaspoon of flaxseed flour 30 minutes previously. DIAGNOSES: A skin prick test for heated flaxseed flour extract showed negative responses, but intradermal test showed positivity which suggested an Immunoglobulin E-mediated reaction. INTERVENTIONS: The patient was instructed to avoid future ingestion of flaxseed. OUTCOMES: The patient had no recurrence of symptoms at 1-year follow-up. LESSONS: This is the first case of flaxseed-induced anaphylaxis in Korea, confirmed by an intradermal skin test.
[Mh] Termos MeSH primário: Anafilaxia/etiologia
Linho/efeitos adversos
Hipersensibilidade Alimentar/etiologia
Sementes/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
República da Coreia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008220


  10 / 16001 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457642
[Au] Autor:Wasan A; Nanda A
[Ad] Endereço:Allergy and Asthma Center, McLean, Virginia.
[Ti] Título:Systemic reaction to timothy grass pollen sublingual immunotherapy.
[So] Source:Ann Allergy Asthma Immunol;118(6):732-733, 2017 Jun.
[Is] ISSN:1534-4436
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anafilaxia/induzido quimicamente
Pólen/efeitos adversos
Rinite Alérgica Sazonal/prevenção & controle
Imunoterapia Sublingual/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Phleum
Extratos Vegetais/efeitos adversos
Extratos Vegetais/imunologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE



página 1 de 1601 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde